Southern Company Indefinite-Lived Research and Development Assets remained flat by 0.0% to $75.00M in Q1 2026 compared to the prior quarter. Over 3 years (FY 2020 to FY 2025), Indefinite-Lived Research and Development Assets shows relatively stable performance with a 0.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates aggressive investment in external innovation, while a decrease may signal project completion, commercialization, or impairment charges.
This represents the value of acquired in-process research and development (IPR&D) projects that have not yet reached com...
Common in pharmaceutical and medical device sectors where M&A is a primary driver of R&D pipelines.
indefinite_lived_rd_assets| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q3 '23 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Value | $75.00M | $75.00M | $75.00M | $75.00M | $75.00M | $75.00M | $75.00M | $75.00M | $75.00M | $75.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| YoY Change | — | — | — | — | +0.0% | +0.0% | +0.0% | +0.0% | — | — |